Spruce Biosciences, Inc. (SPRB) stock
SPRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$43.31+0.42 (+0.98%)
Close on Nov 13, 2026Market cap $124.47MP/E –Yield –
Earnings
Spruce Biosciences's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Mar 8, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$8.51
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Spruce Biosciences's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 8, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 9, 2026before the open | – | – | -$8.51 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 12, 2026before the open | – | – | -$6.68 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 13, 2026before the open | – | – | -$8.94 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 9, 2026before the open | – | – | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 10, 2025during market hours | – | – | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 14, 2025during market hours | – | – | -$3.50 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 6, 2025during market hours | – | – | -$0.32 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 12, 2024before the open | $600.00K | -80.6% | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 12, 2024during market hours | $1.60M | -27.3% | – | Release |
| Q1 FY2024ended Mar 31, 2024 | May 13, 2024during market hours | $2.00M | 0.0% | -$0.28 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 13, 2024during market hours | – | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 13, 2023during market hours | $3.10M | – | -$0.30 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 14, 2023during market hours | $2.20M | – | -$0.32 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 15, 2023before the open | $2.00M | – | -$0.40 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 16, 2023during market hours | – | – | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 10, 2022during market hours | – | – | -$0.48 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 10, 2022during market hours | – | – | -$0.51 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 11, 2022during market hours | – | – | -$0.50 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 14, 2022during market hours | – | – | -$0.39 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 15, 2021during market hours | – | – | -$0.49 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 10, 2021during market hours | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 12, 2021during market hours | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 22, 2021during market hours | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 18, 2020during market hours | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Spruce Biosciences has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Spruce Biosciences puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Spruce Biosciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- News
- News
- Results
- Update
- Update
- Results
- Results
- Results
- Update
- Results
- Results
- Results
See a number that looks wrong?